Facts: Stephen Brook Toban entered a consulting agreement with Columbia Capital Inc. (CCI) on June 1, 2015, to identify a South Korean company for a public listing in British Columbia. Toban facilitated a deal with Biocurepharm Corporation, which listed via a reverse takeover. He claims he wasn't fully compensated, including for monthly fees, investor relations work, and commissions.

Issue: Toban seeks damages for breach of contract, alleging unpaid fees and hidden investments under "secret agreements." CCI and Jai Lee counterclaim, asserting Toban defamed Lee by emailing the Target Company's principal, criticizing Lee's business ethics and competence.

Court's Ruling: The court examined amendments to the pleadings, focusing on necessary particulars for the defamation counterclaim. It found some amendments too vague and required more specific details to clarify the pleadings. The court allowed certain amendments, provided they included these details and were submitted timely, particularly emphasizing facts to support the justification defense in the defamation claim.

Costs/Damages Awarded: The document does not specify exact costs or damages awarded. Each party was instructed to bear their own costs due to divided success on the procedural issues.